Genomic Determinants of Resistance to Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Francesco Maura(Memorial Sloan Kettering Cancer Center), Kenneth H. Shain(Moffitt Cancer Center), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Praneeth Sudalagunta(Moffitt Cancer Center), Mark B. Meads(Moffitt Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Juan‐José Garcés(Universidad de Oviedo), Holly Lee(University of Calgary), Bachisio Ziccheddu(University of Miami Health System), Edward L. Briercheck(The Ohio State University), Doris K. Hansen(Moffitt Cancer Center), Jamie K. Teer(University of Virginia), Noémie Leblay(University of Calgary), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Ciara L. Freeman(Moffitt Cancer Center), Marios Papadimitriou(Sylvester Comprehensive Cancer Center), Phaedra Agius(New York Genome Center), Paola Neri(University of Calgary), Nizar J. Bahlis(Institute of Cancer Research), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Ariosto Siqueira Silva(Moffitt Cancer Center), Michael Durante(University of Miami Health System), Rachid Baz(Moffitt Cancer Center), Meghan Menges(Moffitt Cancer Center), Ola Landgren(University of Miami Health System), Melissa Alsina(Moffitt Cancer Center), Ross Firestone(Memorial Sloan Kettering Cancer Center), Eric L. Smith(Dana-Farber Cancer Institute), Xiaohong Zhao(Xidian University), Xiaofei Song(Jiangsu University), Sungwoo Ahn(University of Calgary), Benjamin Diamond(Memorial Sloan Kettering Cancer Center), Tomas Jelinek(University Hospital Ostrava), Etta Rozen Füller(Dana-Farber Cancer Institute)
Cited by 9
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k